Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Proto-Oncogene Proteins c-bcl-2 | 6 | 2015 | 127 | 1.580 |
Why?
|
| Fluorodeoxyglucose F18 | 4 | 2024 | 190 | 1.170 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2024 | 26 | 0.900 |
Why?
|
| bcl-X Protein | 3 | 2014 | 53 | 0.900 |
Why?
|
| Nuclear Medicine | 1 | 2024 | 23 | 0.890 |
Why?
|
| Cysts | 1 | 2024 | 51 | 0.880 |
Why?
|
| Genital Neoplasms, Female | 1 | 2024 | 41 | 0.870 |
Why?
|
| Medicine | 1 | 2024 | 56 | 0.870 |
Why?
|
| Prostatic Neoplasms | 1 | 2024 | 393 | 0.690 |
Why?
|
| Apoptosis | 4 | 2015 | 1093 | 0.660 |
Why?
|
| Sulfonamides | 3 | 2015 | 125 | 0.630 |
Why?
|
| Internship and Residency | 1 | 2024 | 443 | 0.610 |
Why?
|
| Cyclin B1 | 2 | 2014 | 5 | 0.590 |
Why?
|
| Proteolysis | 2 | 2013 | 96 | 0.530 |
Why?
|
| Multiple Myeloma | 3 | 2025 | 2934 | 0.490 |
Why?
|
| Mitosis | 3 | 2013 | 88 | 0.480 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2014 | 30 | 0.470 |
Why?
|
| Nitrophenols | 1 | 2013 | 17 | 0.450 |
Why?
|
| Biphenyl Compounds | 1 | 2013 | 31 | 0.450 |
Why?
|
| Cell Survival | 3 | 2015 | 590 | 0.450 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2014 | 85 | 0.440 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2014 | 824 | 0.430 |
Why?
|
| Leukemia | 1 | 2013 | 64 | 0.430 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2013 | 116 | 0.420 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2015 | 315 | 0.400 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2025 | 1160 | 0.400 |
Why?
|
| HeLa Cells | 5 | 2015 | 256 | 0.380 |
Why?
|
| CDC2 Protein Kinase | 4 | 2014 | 16 | 0.360 |
Why?
|
| Humans | 17 | 2025 | 50201 | 0.300 |
Why?
|
| Phosphorylation | 4 | 2014 | 525 | 0.250 |
Why?
|
| Whole Body Imaging | 1 | 2025 | 26 | 0.240 |
Why?
|
| Malacoplakia | 1 | 2024 | 6 | 0.240 |
Why?
|
| Gallium Radioisotopes | 1 | 2024 | 10 | 0.230 |
Why?
|
| Aniline Compounds | 2 | 2015 | 42 | 0.230 |
Why?
|
| Cricoid Cartilage | 1 | 2024 | 11 | 0.230 |
Why?
|
| Central Nervous System Diseases | 1 | 2024 | 26 | 0.230 |
Why?
|
| Prostate-Specific Antigen | 1 | 2024 | 47 | 0.230 |
Why?
|
| Peripheral Nerves | 1 | 2024 | 48 | 0.220 |
Why?
|
| Thyroid Gland | 1 | 2024 | 73 | 0.220 |
Why?
|
| Caspase 3 | 2 | 2014 | 93 | 0.220 |
Why?
|
| Thyroid Dysgenesis | 1 | 2023 | 2 | 0.220 |
Why?
|
| Pheochromocytoma | 1 | 2023 | 36 | 0.220 |
Why?
|
| Sarcoidosis | 1 | 2024 | 44 | 0.220 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2023 | 51 | 0.220 |
Why?
|
| Prostate | 1 | 2024 | 117 | 0.220 |
Why?
|
| Hyperparathyroidism | 1 | 2023 | 31 | 0.210 |
Why?
|
| Parathyroid Neoplasms | 1 | 2023 | 27 | 0.210 |
Why?
|
| Radiography | 1 | 2024 | 485 | 0.210 |
Why?
|
| Adenoma | 1 | 2023 | 111 | 0.200 |
Why?
|
| Education, Medical, Graduate | 1 | 2024 | 213 | 0.190 |
Why?
|
| Kidney | 1 | 2024 | 677 | 0.170 |
Why?
|
| Depressive Disorder, Major | 1 | 2021 | 150 | 0.170 |
Why?
|
| Immunoblotting | 2 | 2014 | 116 | 0.150 |
Why?
|
| Green Fluorescent Proteins | 2 | 2014 | 91 | 0.140 |
Why?
|
| Antineoplastic Agents | 2 | 2015 | 1176 | 0.130 |
Why?
|
| Vinblastine | 1 | 2014 | 23 | 0.120 |
Why?
|
| Tubulin Modulators | 1 | 2014 | 27 | 0.120 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2014 | 26 | 0.120 |
Why?
|
| Immunoprecipitation | 1 | 2014 | 58 | 0.110 |
Why?
|
| Transfection | 1 | 2014 | 354 | 0.110 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2015 | 84 | 0.110 |
Why?
|
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 2014 | 18 | 0.110 |
Why?
|
| Mutant Proteins | 1 | 2013 | 37 | 0.110 |
Why?
|
| Gene Knockdown Techniques | 1 | 2013 | 106 | 0.110 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2014 | 150 | 0.110 |
Why?
|
| United States | 1 | 2024 | 4898 | 0.110 |
Why?
|
| Enzyme Activation | 1 | 2013 | 270 | 0.110 |
Why?
|
| Brain | 1 | 2021 | 1311 | 0.110 |
Why?
|
| Cell Death | 1 | 2013 | 174 | 0.110 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2013 | 183 | 0.100 |
Why?
|
| Blotting, Western | 1 | 2014 | 587 | 0.100 |
Why?
|
| Cell Cycle | 1 | 2013 | 226 | 0.100 |
Why?
|
| Membrane Proteins | 1 | 2014 | 347 | 0.100 |
Why?
|
| Signal Transduction | 2 | 2014 | 1612 | 0.090 |
Why?
|
| Male | 3 | 2025 | 25572 | 0.080 |
Why?
|
| Retroperitoneal Space | 1 | 2024 | 32 | 0.060 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2024 | 20 | 0.060 |
Why?
|
| Extremities | 1 | 2024 | 30 | 0.060 |
Why?
|
| Neoplasm Metastasis | 1 | 2024 | 235 | 0.060 |
Why?
|
| Adrenalectomy | 1 | 2023 | 35 | 0.060 |
Why?
|
| Adrenal Glands | 1 | 2023 | 40 | 0.060 |
Why?
|
| Parathyroid Glands | 1 | 2023 | 20 | 0.050 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2023 | 18 | 0.050 |
Why?
|
| Radionuclide Imaging | 1 | 2023 | 116 | 0.050 |
Why?
|
| Female | 4 | 2025 | 26829 | 0.050 |
Why?
|
| Radiopharmaceuticals | 1 | 2023 | 205 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2024 | 288 | 0.050 |
Why?
|
| Bone and Bones | 1 | 2025 | 477 | 0.050 |
Why?
|
| Retrospective Studies | 2 | 2025 | 6190 | 0.050 |
Why?
|
| Aged | 2 | 2025 | 9505 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2024 | 1041 | 0.050 |
Why?
|
| Neuroimaging | 1 | 2021 | 86 | 0.040 |
Why?
|
| Brain Mapping | 1 | 2021 | 227 | 0.040 |
Why?
|
| Cell Line, Tumor | 2 | 2013 | 1390 | 0.040 |
Why?
|
| Animals | 1 | 2013 | 13141 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 921 | 0.040 |
Why?
|
| Middle Aged | 2 | 2025 | 12356 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2021 | 1145 | 0.040 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2015 | 71 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2015 | 131 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2012 | 83 | 0.030 |
Why?
|
| Paclitaxel | 1 | 2012 | 83 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2012 | 164 | 0.020 |
Why?
|
| Cisplatin | 1 | 2013 | 275 | 0.020 |
Why?
|
| Kinetics | 1 | 2012 | 634 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2013 | 475 | 0.020 |
Why?
|
| Models, Biological | 1 | 2012 | 722 | 0.020 |
Why?
|
| Adult | 1 | 2023 | 13486 | 0.020 |
Why?
|